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AN EDUCATION MODULE FOR ENHANCING CLINICAL AWARENESS OF 
CHAGAS DISEASE  
 
NATHANIEL LUCAS BERNARDO 
 
ABSTRACT 
Background 
 Although Chagas disease is not an endemic health concern in the United States, it 
is prevalent with estimates of approximately 300,000 infected individuals.  Of this, an 
estimated 20 – 30% will develop severe, life-threatening consequences.  While what is 
known about Chagas disease is extensive, there is limited knowledge of this disease, 
especially among medical providers and clinicians in the United States.  In order to 
bridge the gap between what is known about Chagas disease and those who lack this 
knowledge, adequate and effective education interventions must be developed and 
delivered.  Education that is tailored for medical providers and clinicians most likely to 
encounter individuals at greastest risk for having Chagas disease is essential.  Once this 
knowledge is gained, accurate evaluation, diagnosis, and treatment of indivuals with 
Chagas disease may be pursued, ultimately decreasing and preventing disease-associated 
morbidity and mortality. 
Proposal 
Clinicans from six departments (infectious disease, cardiology, internal medicine, 
family medicine, pediatrics, and obstretrics and gynecology) will be recruited from 
Boston Medical Center where they will be given an educational module about Chagas 
		 vi 
disease.  Their knowledge of Chagas disease and how to clinically apply it will be 
assessed prior to the educational module, immediately following the educational module 
and 1-month and 6-months following the educational module. 
Conclusion 
 Chagas disease is a burden to health systems in many countries worldwide 
including the United States, and awareness of Chagas disease is lacking among medical 
personnel of multiple specialities in the United States.  Educational interventions have 
provided knowledge of various diseases leading to protocol development, ultimately 
influencing clinical practice to a degree that reduces morbidity and mortality.  The same 
is needed with respect to Chagas disease.  The goal of this educational intervention is to 
provide a knowledge base through teaching and resources for clinicians to learn, 
understand, and review the steps needed to clinically evaluate, diagnose, and treat 
patients with Chagas disease.  Using the reseach identified in this study as well as the 
proposed educational intervention, it is hoped that this disease burden can be alleviated.     
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INTRODUCTION 
Background 
The Centers for Disease Control and Prevention (CDC) identify Chagas disease as 
one of five neglected parasitic infections, along with cysticercosis, toxocariasis, 
toxoplasmosis, and trichomoniasis.1  It is caused by the protozoal parasite, Trypanosoma 
cruzi, and is predominantly transmitted by the triatomine insect, or “kissing bug”.  
Approximately 8 – 10 million people worldwide have the disease with approximately 
300,000 of those individuals living in the United States.1–4  Additionally, the World 
Health Organization (WHO) estimates that approximately 40 million people are at risk of 
T. cruzi transmission.  According to the WHO, Chagas disease is the leading parasitic 
disease, responsible for the highest disease burden and disability-adjusted life years in the 
Americas.  Of those infected, 20 – 30% will develop symptomatic, potentially life-
threatening disease such as cardiac arrhythmias, congestive heart failure, and 
megaviscera.5   
Adequate evaluation of individuals suspected of having Chagas disease is critical 
in halting disease progression and preventing complications of chronic disease.  The 
evaluation process in the clinical setting involves a thorough patient history and review of 
symptoms, physical exam, and the use of diagnostic tools.  Currently, there are guidelines 
and recommendations that have been appropriated from international practices, and have 
provided the foundation for a systematic basis of evaluation.  Through the combination of 
these steps in the patient encounter, as well as evidence-based evaluation guidelines, it is 
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the hope that clinicians will become comfortable in identifying suspected Chagas disease 
patients and treating them.   
General knowledge and awareness of Chagas disease among clinicians in the 
United States is lacking.6  Research conducted by Stimpert et al. explored the knowledge 
base of Chagas disease of providers in the fields of primary care, infectious disease, 
cardiology, obstetrics-gynecology, and transplantation medicine.6  The study concluded 
that lack of awareness and knowledge deficits were common across all of these 
specialties, albeit not uniformly.  This lack of knowledge, the high number of estimated 
cases in the United States, and the high morbidity associated with chronic Chagas disease 
are primary catalysts for the need to educate clinicans who interact with high risk patients 
on a daily basis.   
Statement of the problem 
The close geographical proximity of the southwestern United States to endemic 
areas as well as the high numbers of migrant populations from these endemic regions 
warrants further investigation into developing a standard approach to clinically evaluate 
and treat persons with Chagas disease.  Although vector-borne transmission of T. cruzi is 
incredibly rare in the United States, the possibility of transmission via other methods such 
as from blood products and vertically from mother to fetus is still plausible.  Along with 
established screening measures and ongoing screening studies, the next step in Chagas 
disease management is what to do once individuals have had a positive screening test.  
There is much room for development in the most effective, cost-efficient, and patient 
centered methods to address, clinically evaluate, and treat Chagas disease.   
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Identification of individuals with Chagas disease in the immigrant population is of 
much importance.  Immigrants to the United States from endemic areas are of greatest 
risk of harboring T. cruzi and, thus, of developing serious and potentially life threatening 
consequences.  The greatest challenge is being able to determine those who are infected 
from those who are not infected.  This is complicated by variations in detectable levels of 
parasitemia and anti-parasitic antibodies in the blood, corresponding to particular phases 
of Chagas disease.5  The prolonged asymptomatic period of time between the acute phase 
and the lethal chronic phase of the disease – known as the indeterminate phase – is also a 
challenge in identifying individuals with Chagas disease. 
Educating clinicians with the greatest potential of encountering patients with 
Chagas disease is the first step to developing clinical knowledge and facilitating clinical 
practices to address Chagas disease.  With education, it is perhaps possible to enable 
effective identification and treatment of individuals with Chagas disease, ultimately 
decreasing disease-associated morbity and mortality.   
Hypothesis 
Clinician participation in an educational intervention program about Chagas 
disease will lead to a significant knowledge gain on the risk factors for Chagas disease 
and on how to clinically identify, diagnose, and treat it.  
Objectives and specific aims 
Given that Chagas disease is not an endemic health concern in the United States, 
clinicians may not be aware of the existence of Chagas disease or may know of it but not 
have the competencies to pursue evaluation, diagnosis, and treatment of their patients.  
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This thesis will present background information on Chagas disease and will outline an 
educational intervention for clinicians.  The goal of this educational intervention is to 
provide a knowledge base through teaching and resources for clinicians to learn, 
understand, and review the steps needed to clinically evaluate, diagnose, and treat 
patients with Chagas disease.  Outlined below are three specific phases this study will 
pursue: 
 
1) Develop an educational module on the components of Chagas disease that will 
be designed to produce a gain in overall knowledge about Chagas disease. 
 
2) Target clinicans with the greatest potential of encountering individuals at 
increased risk for Chagas disease in their daily practices. 
 
3)  Measure retention of knowledge following the educational module. 
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REVIEW OF THE LITERATURE 
Overview 
The history of Chagas disease 
Chagas disease was first described by Carlos Chagas in 1909.7  The disease was 
not considered significant until the 1960s when the WHO reported that Chagas disease 
was prevalent in every country in Latin America with an estimated 7 million people 
infected.2  In 1990, the WHO estimated the global prevalence of Chagas disease at 18 
million people.2  Due to the establishment in 1991 of the Southern Cone Initiative (SCI) 
against Chagas disease by six countries -- Argentina, Brazil, Bolivia, Chile, Paraguay, 
and Uruguay -- and initiatives coordinated by the Pan American Health Organization 
(PAHO) and Central America and Andean Pact countries, the prevalence of Chagas 
disease has declined to an estimate of up to 10 million people.1–4  The success of these 
multinational initiatives predominantly involved screening of blood donors and 
insecticide spraying that cumulated in the total elimination of vector-borne transmission 
in endemic regions.2 
Epidemiology  
Chagas disease, also known as American trypanosomiasis, is caused by the 
parasite T. cruzi and is transmitted to humans and animals by the triatomine insect, or 
“kissing bug.”  Endemically, Chagas disease is most often acquired via vector-borne 
transmission from a T. cruzi infected triatomine insect.  Triatomine insects and, thus, 
Chagas disease have a wide endemic distribution that includes Mexico, Central America, 
and South America.3  In these regions, it is most prevalent in poor, rural areas due to 
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factors such as poor housing structure (e.g. thatch roofing and adobe walls that provide 
nesting sites inbetween crevices and spaces), the use of overhead storage for grain or 
household items in homes, and the presence of domesticated animals.8  
However, Chagas disease is not limited to these regions but is prevalent in the 
United States as well as in Europe.9  While there are established enzootic mammalian 
cycles of T. cruzi in the southern states, the prevalence of Chagas disease in the United 
States is predominantly due to immigrants who acquired the disease in endemic 
countries.5  Current estimates conclude that more than 300,000 people in the United 
States suffer from Chagas disease.1,9,10  This prevalence is derived from the number of 
registered migrants from each Latin American country and the infection rate in each 
respective country.  This assumes that the prevalence of infection in the United States is 
the same as that in the migrant’s home country, limiting the accuracy of this estimate.9   
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Lifecycle 
Figure 1: Parasitic lifecycle of Trypanosoma cruzi11 
 
“An infected triatomine insect vector (or "kissing" bug) takes a blood meal and releases 
trypomastigotes in its feces near the site of the bite wound. Trypomastigotes enter the 
host through the wound or through intact mucosal membranes, such as the conjunctiva 
. Common triatomine vector species for trypanosomiasis belong to the genera 
Triatoma, Rhodnius, and Panstrongylus. Inside the host, the trypomastigotes invade cells 
near the site of inoculation, where they differentiate into intracellular amastigotes . 
The amastigotes multiply by binary fission  and differentiate into trypomastigotes, and 
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then are released into the circulation as bloodstream trypomastigotes . 
Trypomastigotes infect cells from a variety of tissues and transform into intracellular 
amastigotes in new infection sites. Clinical manifestations can result from this infective 
cycle. The bloodstream trypomastigotes do not replicate (different from the African 
trypanosomes). Replication resumes only when the parasites enter another cell or are 
ingested by another vector. The “kissing” bug becomes infected by feeding on human or 
animal blood that contains circulating parasites . The ingested trypomastigotes 
transform into epimastigotes in the vector’s midgut . The parasites multiply and 
differentiate in the midgut  and differentiate into infective metacyclic trypomastigotes 
in the hindgut .”   
 
Modes of transmission 
Vector transmission is the predominant method of transmission of T. cruzi to 
humans and Figure 1 above details the lifecycle of the causative agent.  Transmission can 
also occur through blood transfusion, organ transplantation, ingestion of contaminated 
foods or fluids, as well as from mother-to-fetus, known as congenital transmission.1  In 
endemic regions the primary mode of transmission is via the triatomine insect, while in 
the United States there have only been seven documented cases of vector transmission 
since 1950.5  Therefore, the concern in the United States is not vector transmission of 
Chagas disease but transmission via the other methods and the large immigrant 
populations from endemic areas that are potentially infected with T. cruzi.  While there 
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have only been seven documented transfusion-associated and six organ donation-
associated cases of non-vector-borne transmission of T. cruzi, a study performed in Texas 
from 2008 – 2012 revealed that 1-in-6500 blood donors were T. cruzi positive.5,12  The 
risk of congenital transmission of T. cruzi infected mothers to their fetuses is between 1% 
– 10%, depending on the mother’s anti-parasitic immune response, immunosuppression 
conditions, maternal age and parasitic strain among other factors.5  
Clinical course 
Figure 2 features the phases and clinical course of Chagas disease.  
Figure 2: Natural history of Chagas disease in man13 
 
After exposure to T. cruzi and following a 2-3 week incubation period, the 
individual develops an acute Chagas infection, which can be asymptomatic or 
characterized by fever, fatigue, inflammation at the inoculation site, lymphadenopathy, 
and splenomegaly. The acute symptoms normally resolve within 2-4 months.  
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Inflammation and swelling may occur at the inoculation site and two clinical signs are 
most common.  One sign, known as a chagoma, refers to an erythematous – red, 
indurated or raised, and sometimes ulcerated – wound on the skin at the site of the bite.  
The pathognomonic sign of acute Chagas infection is Romaña’s sign, periorbital swelling 
and inflammation that occurs following contamination of the conjunctiva with the 
infected triatomine’s feces.1  Most patients with acute Chagas disease are asymptomatic 
or have mild, nonspecific symptoms which go unnoticed or unattributed to Chagas 
disease.  As such, many individuals do not seek treatment for their acute infection which 
can progress to chronic Chagas disease.5   
  Following the acute phase in Chagas, an untreated individual remains 
chronically infected with T. cruzi and advances to the indeterminate form.  In the 
indeterminate form, patients are clinically asymptomatic with no evidence of organ 
pathology – as determined by electrocardiography and radiography – but remain 
seropositive with IgG specific antibody to T. cruzi.  These individuals will either remain 
in this phase (70 – 80%) or will advance to chronic Chagas disease (20 – 30%).13  In 
chronic Chagas disease, infected individuals may not experience symptoms for decades, 
with estimates of as long as 20 – 30 years after initial infection.13  Long-term health 
consequences in the chronic phase are most notably cardiac and gastrointestinal, 
including but not limited to: cardiomyopathy, arrhythmias, congestive heart failure, 
megaviscera, and more rarely polyneuropathy.14 
Diagnosis  
Aside from clinical evaluation, diagnosing Chagas disease is multifactorial and 
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requires several different testing methods.  Each phase of the disease – acute, 
indeterminate, and chronic – is associated with different concentrations of parasite in the 
blood.  Thus, each phase requires different laboratory techniques for diagnosing 
infection.5 
In acute Chagas disease, trypomastigotes circulate in the blood and microscopy 
can be used to examine fresh blood for the prescence of these mobile trypomastigotes.15  
Another microscopic method uses a staining technique known as Giemsa staining which 
can reveal parasitic morphology on blood smears.15  Hemoculture can also be used but 
requires lengthy growth time on blood medium to provide results.  Lastly, polymerase 
chain reaction (PCR) is one of the most sensitive diagnostic methods for diagnosing acute 
Chagas disease because of its ability to amplify DNA sequences of the parasite while 
eliminating user error from microscopy.5,16 
Diagnosing chronic Chagas disease requires slightly different techniques due to 
decreased levels of parasitemia, whether treatment occurred in the acute phase or not.  
Trypomastigots in the blood are undetectable by microscopy during this phase and PCR 
is often insufficient due to highly variable sensitivity.5  One of the most common 
methods for detection in this phase is an enzyme-linked immunosorbent assay (ELISA) to 
detect IgG antibodies to T. cruzi in the blood.  In endemic regions as well as in the United 
States, Chagas Stat-Pak with quantitative ELISA kits provide a simple, user friendly 
method requiring only a drop of blood and the naked eye to interpret results eliminating 
the need for elaborate laboratory apparatuses.  This rapid bedside diagnostic tool has a 
reported sensitivity of 98.5% and specificity of 94.5%.4  Used widely in endemic regions, 
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the Food and Drug Administration (FDA) has approved the use of these kits to diagnose 
Chagas disease in the United States. Similarly, the immunofluorescent-antibody assay 
(IFA) detects antibodies against T. cruzi.  It is not fully agreed upon whether ELISA or 
IFA has greater sensitivity and specificity.  This is confounded by the complex issue of 
diagnostic tests being developed with antigens from South American strains of T. cruzi 
that may differ from Central American or Mexican strains of T. cruzi, and therefore these 
tests may give false negative results in patients with Chagas disease acquired in Central 
America and Mexico.  Therefore, both tests are recommended to confirm a diagnosis of 
chronic Chagas disease.5,16  These techniques are used in conjunction with 
symptomatology to diagnose and classify infection during the indeterminate phase of 
Chagas disease.  
Treatment 
Two anti-parasitic pharmacologic agents are used to treat Chagas disease: 
nifurtimox and benznidazole.  Nifurtimox was developed in 1967 and benznidazole in 
1972 with the latter being the first line treatment due to fewer side effects.2  In endemic 
regions, these drugs are made available free of charge by the WHO and PAHO. In the 
United States, the FDA has only approved and licensed benznidazole for use in children 
aged 2 – 12.2,17  Nifurtimox is not a licensed medication in the United States, and 
therefore can only be distributed by the CDC under a FDA approved expanded access 
protocol.17  Table 1 refers to current CDC recommendations for treating Chagas disease.17   
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Table 1: Dosing and duration of Chagas treatment17 
Drug Age Group Dosing and Duration 
Benznidazole < 12 years of age 5-7.5 mg/kg per day orally 
in 2 divided doses for 60 
days 
 ≥ 12 years of age 5-7 mg/kg per day orally in 
2 divided doses for 60 days 
Nifurtimox ≤ 10 years of age 15-20 mg/kg per day orally 
in 3-4 divided doses for 90 
days 
 11-16 years of age 12.5-15 mg/kg per day 
orally in 3-4 divided doses 
for 90 days 
 ≥ 17 years of age 8-10mg/kg per day orally 
in 3-4 divided doses for 90 
days 
 
Many studies have shown that benznidazole is effective at eliminating infection 
with T. cruzi.  In a study examining seroconverstion rates among individuals with chronic 
indeterminate Chagas, following 60 days of benznidazole treatment, 86.7% and 95% of 
individuals had a negative PCR response 180 and 360 days since initial treatment, 
respectively.18  Unfortunately, there was also significant treatment discontinuation with 
32% of individuals on benznidazole treatment stopping therapy due to side effects, 
largely consisting of cutaneous reactions, nervous system dysfunction, and 
gastrointestinal symptoms.18 
In the 1960s and 1970s when these two medications were developed, they were 
only used for treatment of acute Chagas due to increased side effect profiles and less 
likelihood to provide a cure in cases of treatment of chronic disease.  However, new 
research has shown the benefits of treating those with chronic Chagas based on factors 
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such as age, disease progression, and co-morbidities.  Recently, studies have shown that 
treatment of chronic Chagas disease in children with benznidazole has resulted in greater 
than 50% cure rates, measured by negative serological tests.5  Similar studies on adult 
cases have mirrored the results of those on children and have additionally shown a 
decrease in progression to Chagas associated cardiomyopathy.5  However, on the 
contrary, a study by Morillo et al. investigated the use of benznidazole as treatment for 
individuals with established Chagas’ cardiomyopathy.  They discovered that 
benznidazole was effective in reducing detectable parasitemia; however it did not reduce 
cardiac progression of the disease.19 
The use of nifurtimox has fallen out of favor given its greater side effect profile, 
yet it is still used as an alternative treatment if benznidazole is not well tolerated.4  Recent 
literature on treatment trials has focused more on benznidazole as opposed to nifurtimox 
because of the lessened side effect profile and effective parasiticidal activity.  Table 2 
highlights several clinical trials performed that have thoroughly examined these two 
medications and their anti-parasitic outcomes. 
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Table 2: Prospective controlled trials of benznidazole and nifurtimox for chronic 
Chagas disease4 
 
 There are more reported common and serious side effects with nifurtimox.  These 
include gastrointestinal side effects, which occur in 30 – 70% of patients, most notably 
weight loss, nausea, vomiting, and abdominal pain.4,17  Neurotoxicity is also common 
manifesting as dizziness, insomnia, and irritability.  More rare serious side effects include 
polyneuropathy and paresthesias.1,5  Common side effects of benznidazole include 
allergic dermatitis most often due to photosensitization, weight loss, and insomnia with 
more serious side effects being peripheral neuropathy and bone marrow suppression.1,5 
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Prevention 
Vector control 
In the endemic regions of Latin America vector control has proved to be the most 
effective method in limiting disease transmission.  To understand vector control, it is 
important to understand the relationship and interactions between triatomines and 
humans.  Three important aspects of this are: 1) the presence of sylvatic populations of 
triatomines or triatomines that live in non-human or wild habitats, 2) the level of 
intrusion of these sylvatic populations in peridomiciles (latrines, outhouses, and 
domesticated animal dwellings) and inside domiciles, and 3) the level of domiciliation or 
domestication (adapting from primarily wild habitats to human or domesticated habitats) 
in peridomiciles and inside houses.20   
The SCI against Chagas disease developed strategies to eliminate the predominant 
domestic vector, Triatoma infestans, via insecticide spraying in homes.  The initiative is 
regarded as highly successful having eliminated transmission in Chile, Uruguay, and 
large parts of Brazil and Argentina by T. infestans.7,13,20  One factor contributing to the 
success of the SCI was that this species of triatomine is exclusively domesticated, living 
only in human homes.20  The lack of sylvatic, or “wild”, populations of triatomines 
limited the re-infestation of homes, disrupting transmission. Control of non-domesticated 
species of triatomines insecticide through spraying typically requires serial applications 
on a yearly or biannual basis.  This can be challenging due to the sheer amount of 
insecticide recquired and the remoteness of many villages.   
	17 
This led to studies implementing spatial blockades to prevent triatomine insects 
from entering homes.  These strategies include window screens and bed nets, which have 
shown promise for reducing triatomine insects in homes as well as sustainability due to 
low maintenance effort and repair needs and longevity of use of these methods in 
community-based transmission prevention programs.21  In addition, improving housing 
conditions also plays a role in vector control.  For domesticated, peri-domesticated (living 
in domesticated animal habitats or human habitats aside from the main living quarters 
such as latrines, outhouses, and food storage buildings), and intrusive (wild populations 
whom approach and enter human habitats) species of triatomine, preventing a viable 
habitat within human homes proves a way to reduce the risk of infection.  Home 
improvements often considered are: wooden walls with plaster or sealant, tile roofing, 
and sealed flooring.  The goal of these improvements is to decrease accessibility into 
homes and eliminate nesting areas (i.e. within crevices and thatched roofing) for 
triatomines once inside the home.8  
In the United States vector control is not the first line strategy for reducing the 
prevalence of Chagas disease.  In the United States, there are 11 different species of 
triatomines across 27 states, with at least 8 known to harbor T. cruzi.10  As mentioned 
previously, there are only seven documented cases of vector transmitted Chagas disease 
in the United States, and although the risk of vector transmission in the United States is 
low, it cannot be neglected.5  Many studies have shown the presence of T. cruzi in a large 
proportion of sampled wildlife attributed to sylvatic populations of triatomines.5,22–24  A 
study that took place at the site where one of the autochthonous cases of Chagas disase is 
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reported discovered that 60% (180 / 298) of triatome species collected where positive for 
T. cruzi.25  Additionally, T. cruzi infection has been reported in domesticated dogs 
throughout the United States.5  Although it may be rare, the possibility of vector 
transmission still remains and may proliferate with more human-wildlife interactions.5,26 
Screening 
Beginning in the 1990s, international organizations, specifically PAHO and the 
SCI, instigated screening as a supplement to vector control in eliminating transmission of 
Chagas disease.  Not only has screening assisted in decreasing the prevalence of Chagas 
disease, it has provided a means to identify infected individuals allowing them to seek out 
treatment and potential cure.  Beginning in 2005 Spain required mandatory screening for 
blood donors born in endemic areas, donors whose mothers were born in endemic areas, 
and individuals who received blood transfusions in endemic areas.9  Similarly, Argentina 
developed a national institute, the National Program for Control of Chagas Disease in 
Argentina, to devise a set of prevention strategies that included non-vector transmission 
control.  While a portion of this program included vector control, a large facet was 
dedicated to prevention via screening methods, particularly focusing on transmission 
from blood products and congenital transmission.  The program also utilized screening 
methods to identify and control acute and chronic infection in T. cruzi carriers, as well as 
establish political, national, and local infrastructure support for screening practices, 
resources, and community involvement.27  These two countries provide novel examples of 
Chagas screening taking place in an endemic area (Argentina), as well as a non-endemic 
area with a population of immigrants from endemic areas (Spain).  Screning in the United 
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States continues to be a work in progress, with one screening protocol being developed 
and piloted in Massachusetts.28  Screening for Chagas disease, however, is not standard in 
all endemic and non-endemic countries limiting its ability to decrease the prevalence and 
disease burden. 
 
Existing research 
 Given the non-endemic roots of Chagas disease in the United States, clinicians 
may not be aware of its existence within the states, much less have the requisite 
knowledge to diagnose and treat patients.  One study suggested a lack of general 
awareness of Chagas disease among clinicians in several medical specialties (Table 3).6  
As displayed in Table 3, obstetricians-gynecologists are the least knowledgeable whereas 
infectious disease specialists are the most knowledgeable with regards to the questions 
posed in the study.  While infectious disease specialists outperform their medical 
counterparts in all but one category, this study shows that there is still room for 
improvement in this specialty as well as across all of these medical fields. 
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Table 3: Knowledge about Chagas disease6   
 
 
Given this lack of awarenss, the development of educational materials and 
educational initiatives based from research and studies is needed.   Of utmost importance 
is assessing the risk of disease among immigrants in the United States and educating 
clinicians on this risk.29  Awareness that Chagas disease exists and knowing how to 
address it when it presents itself are intertwined.  Only 11% of positive donors or their 
clinicians seek treatment and only 25% of positive donors received follow-up care.6,29 
A study by Basile et al. discusses populations in which screening would be most 
beneficial.30  It outlines that screening should be offered to all Latin Americans who have 
potentially been exposed to the reduvidae insect or to contaminated blood products, to 
mothers and expecting mothers from endemic areas, to children whose mothers were 
born in endemic areas, and to all family members with a reported case in the household.  
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The study also concludes that patients who may receive the greatest benefits from 
treatment should have every opportunity to be screened.  These populations include: 
women of childbearing age, young patients, transplant recipients, and immunosuppressed 
patients.  This should not deter individuals who do not fall within these populations from 
pursuing screening, but it points out that these populations specifically would perhaps 
benefit the greatest from standardized screening protocols.  Additionally, blood, blood 
products, and donated organs by people from endemic regions should be screened. 
Currently, the only standard screening measure in the United States, approved by the 
FDA in 2006, is ELISA to screen for T. cruzi antibodies in blood donations.3,5  This 
screening directive is able to identify individuals with indeterminate and chronic Chagas 
disease and is important in preventing transmission, however, this screening method does 
not provide the means to identify individuals with acute Chagas infection. 
A systematic review carried out by Bern et al. on the evaluation and treatment of 
Chagas disease in the United States expounds on their evidence-based synthesis (Figure 
3).4   
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Figure 3: Baseline evaluation of the patient newly diagnosed with chronic 
Trypanosoma cruzi infection4 
 
 
In the case of a new diagnosis of Chagas disease, the patient should undergo a full 
medical history and physical exam as well as a resting 12-lead electrocardiogram 
(ECG/EKG) with a 30-second lead II rhythm strip.  Based on this three part evaluation, 
the patient will fall into varying sets of recommendations.  If the initial evaluation is 
normal, the three part evaluation is recommended an an annual basis.  If Chagas-
associated heart disease is suspected, a 24-hour ambulatory ECG/EKG, echocardiogram, 
and exercise testing are recommended.  If following the initial evaluation, gastrointestinal 
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symptoms are present, barium contrast studies are recommended.4 
A review of Chagas diasese by Perez-Molina et al., published in January 2018, 
presents a similar schematic for the diagnosis and evaluation of patients with chronic 
Chagas disease (Figure 4).31   
Figure 4: Assessment of patients with chronic Chagas disease31 
 
Like the review by Bern et al., Perez-Molina et al. present the course of from 
onset of clinical suspicion of Chagas disease.4,31  An aspect this review does add is 
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recommendations for whom to treat.  In terms of chornic Chagas disease, treatment is 
dependent on the disease phase and involvement of certain organ systems. 
In cases of acute or congenital Chagas disease, reactivated infection, and chronic 
Chagas disease of individuals under the age of 18 years, treatment is recommended.  For 
individuals aged 19 – 50 years without advanced heart disease, treatment may slow 
development and progression of heart disease.  For individuals 50 years old and older, 
treatment is considered optional; Chagas-associated heart disease tends to be more severe 
which leads to reduced efficacy and greater side effect profile of the medication.4  
Individualized treatments should routinely be applied taking into consideration potential 
treatment benefit, course of treatment, and medication side effects.   
 Cardiovascular complications are the most common consequences of untreated 
chronic Chagas disease and largely dictate prognosis.  Many classification schemes have 
been developed that stage known cardiovascular complications due to Chagas disease.  
These are predominantly determined by ECG/EKG findings and congestive heart failure 
status as measured by chest radiography and echocardiography.  One classification 
scheme used in Latin America integrates the American College of Cardiology / American 
Heart Association classification system for staging heart failure (Table 4). 
Table 4: Association between Chagas disease and cardiovascular complications: 
classification incorporating American College of Cardiology / American Heart 
Association staging4 
Stage ECG 
A Normal ECG findings, normal heart size, normal LVEF, NYHA 
class I 
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B Abnormal ECG findings, normal heart size, normal LVEF, NYHA 
class I 
C Abnormal ECG findings, increased heart size, decreased LVEF, 
NYHA class II – III 
D Abnormal ECG findings, increased heart size, decreased LVEF, 
NYHA class IV 
Abbreviations: CHF, congestive heart failure; ECG, electrocardiogram; LVEF, left 
ventricular ejection fraction; NYHA, New York Heart Association 
 
 
Intricacies and efficacy of educational interventions in the literature 
Continuing education is an intrinsic pillar in the medical field.  Young clinicians 
spend many years in structured education programs before venturing out into autonomous 
practice where on the job learning becomes a staple.  Because of this constant exposure 
many methods have been utilized to deliver medical knowledge including: lectures, group 
discussions, grand rounds, personal learning, continuing education seminars, as well as 
the utilization of on-site support personnel.  There has been much debate and research 
into how to best deliver this knowledge so that clincians better retain and are able to use 
what is learned in practice to ultimately improve health care and patient outcomes.32 
Studies have exhibited that didactic, classroom-based trainings, a common form 
of capacity development, are not sufficient to ensure adherence to clinical guidelines and 
often lead to clinicians spending more time away from their clinical settings and 
patients.32  Based on this, it seems that in-house teaching would yield greater retention in 
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material that is taught and positively affect clinical practice.  Having the appropriate 
teacher or facilitator is also important.  O’Brien et al. describes educational outreach as, 
“a personal visit by a trained person to health professionals in their own settings.”33   
Futhermore, curriculums should be tailored to supply the necessary components for 
specific environments and should be self-sustaining.  A study by Rubenstein et al. 
concluded that sustainable, long-lasting quality improvement is built on the backbone of 
three necessary features: 1) systematic data guided activities, 2) designing with local 
conditions in mind, and 3) iterative development and testing.34  A study that focused on 
decreasing catheter-related bloodstream infections in the surgical intensive care unit used 
a 10-packet self study module that included information on the following topics: a) 
epidemiology and scope of the problem, b) risk factors, c) etiology, d) definition, and e) 
methods to decrease risk.35  This study yielded a statistically significant decrease in 
catheter-related bloodstream infections by 66% following the educational intervention.35   
There exists a void in literature that pertains to using educational interventions to 
raise awareness and knowledge of Chagas disease.  Without awareness and knowledge of 
Chagas disease, the ability of clinicians to recognize and properly treat it is difficult.  
This study will provide an educational methodology to address the lack of knowledge of 
Chagas disease with the goal of knowledge retention of Chagas disease among clinicians.     
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METHODS 
Study design 
This study will utilize a pre- and post-intervention observational approach to 
determine clinicans’ knowledge of Chagas disease before and after participating in an 
educational intervention.  In order to measure knowledge of Chagas disease, selected 
participants will perform a pre-intervention assessment, followed by provision of an 
educational curriculum and post-intervention assessments immediately following and at 
1-month and 6-months post-intervention.  The study will be implemented among six 
departments at Boston Medical Center (BMC) in Boston, Massachusetts and the duration 
of data collection and assessment will take approximately 12 months. 
Study population and sampling 
For the fiscal year of 2016, BMC had over 1,500 staffed physicians, fellows, and 
residents (data on physician assistants and nurse practicioners is unknown).36  Clinicians 
will be recruited with help through department chairs, as well as residency and fellowship 
program directors.  Clinicians (attending physicians, residents, physician assistants, and 
nurse practicioners) will be randomly selected from six departments within BMC to 
receive the educational module.  The selected departments will be those with the potential 
of encountering patients most at risk of having Chagas disease.  The departments will 
include: infectious disease, cardiology, internal medicine, family medicine, pediatrics, 
and obstretrics and gynecology.  Listservs of clinicans actively practicing within the 
aforementioned departments will be obtained from hospital administration.  Table 5 
details the eligibility criteria for the study population.  Sample size was estimated using 
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McNemar’s test with an alpha level of 0.05, power of 80%, a no pass-pass proportion of 
0.595, and pass-no pass proportion of 0.045.  Based on these paramters the sample size 
was estimated at 14, therefore, it is feasible that clinicians among the six BMC 
departments will provide an appropriate sample.  A total of 14 clinicans will be randomly 
selected from each of the six departments (n=84) to participate in the study.  Taking into 
account 15% loss to follow-up, an additional 2 clinicians will also be randomly selected 
from each of the six departments (n=12) to participate in the study, bringing the total 
number of participants to 96. 
Table 5: Study population eligibility criteria 
Inclusion Criteria Clinician is based at BMC 
Active inpatient and outpatient care of 
patients 
 
Clinicians have scheduled time for 
learning during their work weeks 
 
Exclusion Criteria Anticipation of leaving BMC within 
evaluation period lasting 6-7 months 
 
Clinicians hired or incoming fellows and 
residents following the educational 
intervention 
 
Intervention 
 Each subject will then receive a 10-page educational packet designed by a 
member of the research team using CDC fact sheets and printable resouces that will 
outline the following topics on Chagas disease:37 
• Epidemiology 
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• Risk Factors 
• Etiologic Agent & Transmission 
• Clinical Course & Symptomatology 
• Diagnostic Techniques 
• Treatment 
• Prevention 
• Screening 
 A PowerPoint presentation will be developed by a member of the research team 
using the CDC fact sheets and printable resouces along with 2-3 patient cases written by 
the research coordinator.  There will be no further education at the 1-month and 6-month 
marks. 
Study variables and measurement tools 
Prior to use in this study, the assessment will undergo a pilot trial to determine if 
it is at the appropriate education level of the study population.  The assessment will be 
distributed to clinicians in the fields of infectious disease, primary care, and obstetrics 
and gynecology at BMC-affiliated health centers.  Pass-fail rates will be calculated and 
examined to identify difficulty of assessment, and input on confusing questions will be 
solicited from the pilot test participants. 
Table 6 below highlights the topics for which assessment questions will be 
derived.  Gross scores of each assessment at each time point will be calculated.  Each 
individualized score will be trended to gauge retention in knowledge.  A “passing” score 
will be: ≥70%.  We will also look at the percentage of shift from non-passing scores to 
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passing scores from the pre-educational intervention assessment to the immediate post-
educational intervention assessment. 
Table 6: Question topics for assessment tool 
Assessment structure: adapted from Rodrigues et al.38 
Question topics: Question breakdown: 
 
Knowledge 3 on clinical aspects of the disease 
 
 
  
2 on risk factors 
 3 on serological tests 
 
 2 on treatment 
 
 4 on epidemiological surveillance 
 
 Sub-total: 14 
 
  
Practices 3 on diagnosis and pre-test/post-test 
counseling 
 
 2 on treatment 
 
 1 on treatment counseling 
 
 Sub-total: 6 
 
  
Total number of questions: 20 
 
 
Recruitment 
It is important to establish this study in a location and health center that serves 
those at risk.  As mentioned in the review of literature, individuals who have immigrated 
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from endemic countries pose the highest risk for harboring T. cruzi.  Boston Medical 
Center is one of the leaders in Massachusetts for serving a diverse population of patients, 
including those of latino/Hispanic ethnicity.39  Initial contact will be made with 
department chairs and residency and fellowship program directors by research personnel 
who will describe the study and determine the best days and times to schedule in house 
teaching and data collection.  Prior to the day in which the educational intervention will 
be performed, they will also be provided with a standardized email that oulines the 
educational intervention for them to send to clinicians in their departments.  Also, 
announcements of the educational intervention will be made at grand rounds and 
department meetings.   
Data collection 
The pre-test, education module, and immediate post-test will be inserted into each 
department’s education curriculum and substituted for a grand rounds presentation or 
arranged as a lunch-education talk in order to retain interest in the study without taxing 
clinicians’ schedules.  To ensure subjects fall within the six selected departments, they 
will be asked to sign in prior to the start of the initial pre-test and successive post-tests. 
The entire sample population will first take the pre-intervention assessment which 
will be collected and individual scores calculated behind closed doors.  Subjects will not 
be made aware of their scores.  A member of the research team will present the 
PowerPoint which should take approximately 30 – 45 minutes.  Following presentation of 
the PowerPoint, subjects will take the immediate post-intervention assessment.  
Following completion, the test with corrent answers identified will be reviewed with the 
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participants, collected, and the score calculated behind closed doors.  The pre-test, 
distribution of educational packets, presentation, and immediate post-test should take 
approximately 1 hour and 30 minutes to complete.  At both 1-month and 6-months 
following the day of the immediate post-test, the assessment will be distributed to those 
who underwent the educational intervention prior to the start of a grand rounds 
presentation. 
The assessment at all four intervals: pre-intervention, immediate post-
intervention, 1-month post-intervention, and 6-month post-intervention will be identical.  
Assessments will be distributed in paper form, collected, and imputed into a 
computerized storage file using Microsoft Excel 2016 (or similar platform).  For the intial 
and each successive assessment, participants will use a unique identification code in 
order to trend test scores. 
Data analysis 
Data will be analyzed using the statistical software program SPSS.  The 
knowledge of clinicans pertaining to Chagas disease between the pre- and post-
intervention assessments will be compared using the McNemar’s statistical test.  Results 
will be examined by department.  Percentages of passing grades on pre-test will be 
compared to 1) immediate post-test, 2) 1-month post-test, and 3) 6-month post-test.  Pre- 
and post-test scores will be compared by Wilcoxon signed-rank test.  Ninety-five percent 
confidence intervals will also be determined.  In order to account for multiple 
comparisons, the Bonferroni correction will be used to calculate alpha.  Given the use of 
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three comparisons and a desired alpha of 0.05, the Bonferroni correction would test each 
comparison at α = 0.05 / 3 = 0.0167. 
Timeline and resources 
Assistance in carrying out and helping with the study will include: 1) researchers 
– those involved in planning study, contacting hospital administration, delivering 
education module, collecting assessments, and analyzing data and 2) department chairs 
and chief residents – these individuals will be instrumental in marketing the study among 
their departments. 
The overall duration of this study will take approximately one year.  Month one 
will include study set-up – contacting hospital and department administration, 
coordinating in-house teaching sessions for each of the six departments, and printing 
educational packets.  Beginning at month two, day 1, the pre-test, education module, and 
post-test will be administered.  One month after this, the1-month post-test will be 
administered.  Five months after the 1-month post-test, the 6-month post-test will be 
administered.  Months six through twelve will be reserved for data analysis, statistical 
analysis, and interpretation of results. 
 
Institutional review board 
A protocol will be submitted to the Boston University Medical Campus 
Institutional Review Board for exempt approval.  This will indicate the minimal risk to at 
risk patients and potentially alleviate future, preventable disease associated morbidity and 
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mortatliy.  If the IRB determines that the project does not meet the criteria for exempt 
approval, expedited approval will be requested. 
 
CONCLUSION 
Discussion 
Studies show that education programs lead to better outcomes in clinical 
practice.33,35,38  Ideally, the purpose of this study will provide a model that is effective in 
retention of knowledge on Chagas disease.   
One limitation that may affect the assessment of the educational intervention is 
knowledge of Chagas disease gained from other sources such as through literature, the 
internet, television, or radio during the study period.  For instance, if the entire pediatric 
resident class decided to have monthly review sessions on infectious diseases in children 
that included Chagas disease, their performance on the 6-month post-intervention 
assessment may potentially be higher than the family medicine residents.  Ultimately the 
value of this study’s educational intervention would be skewed.  To minimize 
confounding, the educational intervention described in this study would be the only 
information on Chagas disease clincians would hear or be able to refer to during the study 
period.  However, discouraging the use of other sources would do a disservice to 
academic pursuit and to the Hippocratic Oath. 
As with any study, one must consider subject drop-out.  This thesis proposes a 
study timeline in which residents will remain in whichever postgraduate year they are in, 
preventing loss of an entire resident class due to graduation and or addition of an extra 
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due to matriculation.  However, drop-out is inevitable as employeed physicians may 
change jobs, clinicians may not attend the initial mandatory session or participate in the 
follow-up assessments for various reasons, and residents may take time off or 
spontaneously pursue continuation of their training at an away site.  For the purposes of 
this study, drop-out was accounted for in sample size calculations by assuming 15% lost 
to follow-up.  Drop-out will be recorded and monitored throughout the duration of this 
study as well.  Also, in order to obtain a significant difference in comparing scores 
between the pre-test to the immediate post-test, 1-month post-test, and 6-month post-test, 
the Bonferroni correction will be used to calculate alpha, or power.  If this educational 
intervention proves successful, it could be tested among larger health systems with even 
more clinicians. 
Another potential limitation is the use of the identical testing assessments at each 
testing interval.  This may cause assessment bias in that study participants may learn the 
correct answer without necessarily having a broader knowledge on the subject.   
Summary 
Chagas disease has been well documented on an international scale.  In 1990 there 
were 18 million documented cases worldwide which has decreased to 8 – 10 million 
cases worldwide at present.1–4  A predominant factor in the large decrease in disease 
prevelance was vector control in several endemic South American countries.  A key 
feature of the eradication program was educating the common people about taking steps 
to prevent the vector from infesting their homes.   
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As in this case, education is a huge factor in facilitating outcomes.  By educating 
clinicians in the United States, there is real potential to identify and treat people with 
Chagas disease.  Of the 8 – 10 million people worldwide with the disease, approximately 
300,000 of those individuals are living in the United States and 20 – 30% of these people 
will develop serious, life-threatening consequences if left untreated.  Thus, this 
intervention has the potential to save or greatly improve 60,000 – 90,000 lives.  To put 
these numbers into context, the Cystic Fibrosis Foundation reports more than 30,000 
people with cystic fibrosis are living in the United States and over 70,000 people with 
cystic fibrosis are living worldwide.40  The difference in prevalences between these two 
diseases is great, yet the disease affecting fewer individuals is more well known.  This is 
not to say that cystic fibrosis should not receive the heightened education, research, and 
funding it has received, but it simply highlights that the knowledge of this particular life-
threatening disease is better retained and awareness of the disease is greater. 
Clinical and/or public health significance 
The educational intervention proposed in this thesis will aim to bridge the 
knowledge gap of what is known about Chagas disease among the clinicians whom 
interact with high risk patient populations.  If the aim of this study is achieved, the 
protocol used in this study may be used in other hospitals and clincs as well.  Also of 
importance is the minimized time burden of the intervention.  The educational 
intervention proposed in this study will be incorporated into the educational curriculums 
already in place in the departments from which the study population will be drawn from.  
This will decrease the amount of time that clinicans spend away frm their patients.  
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The goals of this study are not to directly pursue whether clinicians are effectively 
identifying patients with Chagas disease; however, providing clincians with the 
knowledge to be able to do this is an innate outcome.  If this educational intervention 
program is implemented in hospitals and clincis contemplating screening or already in the 
process of screening individuals for Chagas disease, then many people may potentially be 
identified and treated.  This in turn will decrease Chagas disease-related morbidity and 
mortality. 
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